22-09 ADEPPT

Name No. For Patients with Purpose
22-09 ADEPPT 22-09

Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2]

The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2).


22-15 PLAN

Name No. For Patients with Purpose
22-15 PLAN 22-15

Advanced or locally advanced Non-Small Cell Lung Cancer

Purpose of this study is to evaluate whether plasma genotyping via an in-house next generation sequencing (NGS) panel, will identify actionable genomic alterations in patients with newly diagnosed advanced or locally advanced non-squamous NSCLC


23-12 LATIFY

Name No. For Patients with Purpose
23-12 LATIFY 23-12

patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

The purpose of the study is to measure Overall Survival (OS). OS is defined as time from randomisation until the date of death due to any cause. The superiority of ceralasertib plus durvalumab combination therapy relative to docetaxel will be demonstrated by assessment of OS


22-23 NeoCOAST-2

Name No. For Patients with Purpose
22-23 NeoCOAST-2 22-23

Early-Stage (II to IIIA) Non-small Cell Lung Cancer

The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab.


BRAND

Name No. For Patients with Purpose
BRAND 23-11

Non-Small Cell Lung Cancer

The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC


IMMUNO FERTILITY

Name No. For Patients with Purpose
IMMUNO FERTILITY 22-22

Patients of Childbearing Potential who receive ICIs(Immune checkpoint inhibitors) for Cancer

This study will use a number of tests to assess reproductive parameters in patients 1-2 years after they have received ICI therapy to observe the effect that ICI therapy may have on a patient’s fertility.


Krystal-7

Name No. For Patients with Purpose
Krystal-7 22-07

Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This Phase 2 study will evaluate the efficacy and safety of MRTX849 on its own and in combination with pembrolizumab.


AcceleRET-Lung

Name No. For Patients with Purpose
AcceleRET-Lung 20-21

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).


SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours

Name No. For Patients with Purpose
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours 18-33

inoperable, early stage, high-risk ultracentrally located lung tumours.

The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy.